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Despite decades of diﬀerent treatment algorithms, the management of congenital adrenal hyperplasia (CAH) remains clinically
challenging. This is due to the inherent diﬃculty of suppressing adrenal androgen production using near physiological dosing
of glucocorticoids (GC). As a result, alternating cycles of androgen versus GC excess can occur and may lead to short stature,
obesity, virilization, and alterations in puberty. Novel therapeutic alternatives, including new and more physiological means of GC
delivery, inhibitors at the level of CRH or ACTH secretion and/or action, as well as “rescue strategies”, such as GnRH analogs, anti-
androgens, aromatase inhibitors, and estrogen receptor blockers, are available many of these agents, however, still require active
investigation in CAH. Bilateral adrenalectomy is eﬀective but it is also still an experimental approach. Gene therapy and stem cells,
to provide functional adrenal cortical tissue, are at preclinical stage but provide exciting avenues for a potential cure for CAH.
1. Introduction
Appropriate treatment of children with congenital adrenal
hyperplasia (CAH) is challenging because it requires the
simultaneous and continuous control of a number of
physiologic mechanisms. The molecular defect, usually in
the enzyme 21-hydroxylase (21-OH), leads to a decreased
production of cortisol that removes the normal negative
feedback to pituitary corticotrophs [1, 2]. Consequently,
adrenocorticotropic hormone (ACTH) secretion is increased
and drives the shunting of cortisol precursors to androgen
synthetic pathways [3]. To control CAH, therefore, it is
necessary both to adequately replace glucocorticoids (and
mineralocorticoids in salt-wasting forms) and to prevent the
production of excess androgens.
Adequate control of CAH requires life-long glucocorti-
coid (GC) replacement suﬃcient to maintain adrenal andro-
gen suppression. Determining the “optimal level” of GC
replacement, however, can be elusive. Undertreatment leads
to adrenal insuﬃciency and androgen excess, while over-
treatment leads to obesity, iatrogenic Cushing’s syndrome,
and osteoporosis [4–10]. Both under- and over-treatment of
CAH can result in diminished adult height [11–14]. The final
eﬀect on bone age (BA) maturation will reflect the integrated
eﬀect of GCs and adrenal androgens over time, especially in
the prepubertal child.
We present an overview of new/potential treatment
strategies aimed at improving the outcome in patients
with CAH. Included are strategies, such as GnRH analogs,
antiandrogens, and aromatase inhibitors, for which there
are clinical studies completed and/or ongoing to support
their use in CAH. For other approaches, such as bilateral
adrenalectomy and circadian hydrocortisone treatment, the
treatment strategies have already been implemented in the
clinical arena albeit in a small number of cases, but formal
trials are lacking. Finally, we have included several regimens
that have been utilized in other conditions and extrapolated
for use in CAH.
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2. Glucocorticoid-Sparing Strategies
2.1. Corticotropin Releasing Hormone (CRH) Antagonists.
Corticotropin releasing hormone (CRH) is the primary
trigger for ACTH release from pituitary corticotrophs, and
thus, modulation of CRH actions oﬀers an opportunity
to dampen ACTH release. More specifically, inhibition at
this higher level in the HPA (hypothalamic-pituitary axis)
would be expected to result in a decrease in ACTH release.
Inhibition of both CRH and ACTH, in turn, could permit
lower GC requirements to maintain adrenal suppression
while at the same time providing adequate replacement
[15, 16]. Preclinical studies in rodents demonstrate that the
CRH antagonist, antalarmin, blocks CRH1 receptor-induced
increases both in adrenal size and behavioral responses
[17, 18]. CRH analogues with more prolonged action such
as astressin inhibit ACTH release [19], and alpha-helical
CRF 9-41 reduces measures of stress in a sheep [20]. Trials
using CRH (1) receptor antagonists in humans showed a
decrease in CRH-associated signs of anxiety and depression.
However, since the aforementioned studies in sheep and
humans have not been clearly associated with decreases in
CRH-induced ACTH release and/or cortisol levels, the direct
clinical applicability of CRH antagonists to CAH remains
unclear [20, 21].
2.2. Strategies Directly Targeting ACTH Action/Secretion.
Inhibition of either ACTH secretion or action, that is, targeting
the next level of the HPA axis, represents another coher-
ent strategy. The identification of selective melanocortin
receptor subtypes (e.g., MC2-R for ACTH in the adrenal
cortex) opens an avenue to blunt ACTH action at the
adrenal gland and in turn reduce androgen production [22–
24]. Again, this approach could lower GC dosing with the
goal of a more physiologic range, such as that used in
Addison’s Disease (8–10mg/m2/day; [25, 26]) rather than
the “suppressive” regimens (12–15mg/m2/day after infancy;
[27]) usually required for CAH. Preclinical and clinical trials
are needed to ascertain the safety and eﬃcacy of ACTH
receptor antagonists.
Blockade of ACTH release is another approach under
investigation. In vitro studies demonstrated that ACTH
release from corticotrophs is uniquely coupled to the
dihydropyridine-sensitive subclass of voltage-dependent cal-
cium channels, such as nifedipine or amlodipine, that are
typically used to treat hypertension [28–30]. Clinical trials
in Cushing’s disease (another state of ACTH excess) reported
acute decreases in ACTH levels with calcium channel
blockers [31]. Amlodipine is a long-acting antagonist of DHP
calcium channels that has been approved for pediatric hyper-
tension, and it permits accurate daily dosing using a liquid
suspension. We recently completed a placebo-controlled
cross-over clinical trial in 13 children with either simple
virilizing (SV) or salt wasting (SW) CAH (ages 6–12 years of
age). We have found that addition of amlodipine (0.1mg/kg
daily bedtime dosing) can attenuate ACTH levels in children
with CAH ([32]; Loechner, unpublished observation). A mild
elevation in heart rate was observed in 2/13 children during
change in position, but this was not associated with a drop
in blood pressure nor clinical symptoms with the exception
of one child who exhibited mild symptoms of postural
hypotension. It is noteworthy that this child had a SW
CAH, suggesting that this approach may not be appropriate
in such children. These data, however, suggest that the
addition of the calcium channel antagonist, amlodipine, to
CAH treatment regimen may be a safe and helpful adjuvant
therapy in, at least, SV CAH. Longitudinal study is indicated
to assess both eﬀects of calcium channel blockade on long-
term GC dosing, final adult height, and bone density.
Other potential agents to decrease ACTH secretion
include cyproheptadine (a serotonin receptor antagonist),
cabergoline (a dopamine agonist), and valproic acid (a
GABA reuptake inhibitor). Each has been used with limited
success in the treatment of Cushing’s disease and Nelson’s
syndrome [33, 34], but their eﬃcacy in the management of
CAH remains to be studied.
3. Glucocorticoid-Delivery Strategies
3.1. Continuous Subcutaneous Hydrocortisone Infusions
(CSHI). Studies of circadian cortisol therapy, using
hydrocortisone (HC) infusions or modified-release oral
formulations, show that these treatments can better mimic
physiological cortisol rhythm and hence result in better GC
replacement and ACTH suppression in patients with CAH.
Merza and colleagues [35] showed that circadian intravenous
infusions of HC delivered by a programmable pump that
replicated the physiological cortisol circadian rhythm
reduced ACTH and 17OHP levels in two patients with
Addison’s disease and two patients with CAH. In another
study, continuous subcutaneous HC infusion (CSHI) was
evaluated in seven patients with adrenal insuﬃciency and
showed that morning ACTH levels were reduced to near
normal levels, the HC doses were reduced in most patients,
and all patients reported satisfaction with this modality [36].
In another recent report, a 4-year therapy with CSHI proved
eﬀective and well tolerated in a 14-year-old male with CAH.
CSHI treatment produced rapid changes in CAH control
and a 50% reduction in the daily HC dose within the first
3 months. In addition, the patient demonstrated normal
adrenal androgen production and a normal progression
through puberty [37].
These reports hold promise for significant benefits of
CSHI that include: (1) good adrenal androgen suppression
with decreased doses of glucocorticoid and (2) better
management of stress and illness because of the pumps
capacity to provide boluses readily and increased overall daily
hydrocortisone dosing. Hydrocortisone infusions, however,
are impractical for many patients and they pose the risk of
site and pump failures. Development of oral modified-release
formulations of hydrocortisone may be a more practical
solution.
3.2. Dual-Timed/Sustained Release Formulations of HC.
Although studies evaluating various GC preparations and
their timing of administration have been ongoing for years,
no clear-cut regimen has proved universally superior in
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children with CAH. Two GC preparations that exploit the
pharmacokinetic peak of a once daily, dual-timed HC in
order to mimic the diurnal variation peak of ACTH [38, 39]
and, in turn, facilitate more physiologic delivery are under
evaluation. Chronocort, a once daily, dual-timed, sustained
oral release HC appears to be promising. Johannsson and
colleagues [40] reported a peak cortisol level whose onset is
at one hour after oral intake with peak duration of approx-
imately six hours, after that time cortisol levels decreased to
a steady state for the remainder of the day. Chronocort was
studied in an open label cross-over manner and compared
with standard Cortef dosing in the control of CAH [38].
A single oral dose of Chronocort at 2200 compared to
standard three daily doses of Cortef (with a higher evening
dose of Cortef) showed that the Cortef regimen resulted in
three peaks, whereas a single peak at 0600 occurred with
Chronocort. 17OHP levels, androstenedione, and ACTH
levels were all lower during this period with Chronocort
compared to Cortef. However, afternoon “androgen control”
was superior with Cortef because HC levels with Chronocort
waned.
A second sustained preparation is that of Duocort,
whose peak concentration is reached within one hour after
intake. Consequently, the use of Duocort to suppress the
morning ACTH and subsequent androgen surge in CAH
would require taking the medication in the middle of the
night. For children, this would be problematic and will result
in decreased compliance.
These new drug-delivery technologies have a significant
potential to improve and simplify GC replacement therapy
by being more eﬀective, having fewer adverse eﬀects, and
improving compliance. Both long-term eﬃcacy and safety of
these approaches needs to be established.
4. “Rescue” Strategies
When children with CAH are short and/or have a predicted
adult height (PAH) that is significantly below that of their
mid-parental target height (MPH), such that significant
adult short stature is expected (e.g., as assessed by a markedly
advanced bone age), measures beyond standard therapy are
sometimes employed for the physical and psychosocial well-
being of the child. Often, such strategies rely on experience
in other conditions such as precious puberty and McCune
Albright syndrome in which stature has been compromised
due to an advanced bone age driven by excessive androgens
and/or estrogens and the resultant premature epiphyseal
maturation. Moreover, chronically elevated adrenal andro-
gens in children with CAH often associated with late onset of
therapy or poor compliance can result in early puberty due
to early maturation of the HPG axis [41].
4.1. GnRH Agonists with or without Growth Hormone (GH).
As with central precocious puberty, the use of GnRH
(gonadotropin releasing hormone agonists), alone or in
combination with GH, has been shown to improve PAH
[42–45]. The central precocity accompanying CAH has been
shown to respond to GnRH agonists alone as well as in
combination with GH [14, 41, 46–48]. While eﬀective in
stalling central puberty, growth velocity often decreases upon
initiation of GnRH agonist therapy, because it suppresses
the eﬀects of sex steroids on linear growth. GH-induced
improvement in growth velocity occurs in central preco-
cious puberty as well as in CAH [43, 49]. Quintos et al.
[14] reported that GH treatment alone (n = 12) or in
combination with leuprolide acetate (n = 8), a GnRH
agonist, improved growth velocity after 1 (5 ± 1.9 to 7.8 ±
1.6 cm/yr) and 2 (6± 1.6 cm/yr) years of treatment. A similar
improvement in the height SD score for bone age was found
in the treatment groups. Lin-Su et al. [47] demonstrated,
in a subsequent trial in which fourteen children with
CAH were followed to final adult height, that combination
treatment with leuprolide acetate and GH can result in an
improved final adult height by approximately 1SD compared
to matched control children who received standard therapy.
The eﬀect of these agents, and their duration of use on both
the pubertal growth spurt and on bone accretion/peak bone
mineral density are areas that require more study in children
with CAH.
4.2. Antiandrogens. Blockade of excess androgen production
and/or their action is an essential component of CAH
management. The aforementioned strategies have targeted
attenuation of adrenal androgen production throughmanip-
ulation of physiologic feedback loops involving GCs and
the hypothalamus and pituitary corticotroph. An alternative
approach is to suppress the adrenals less rigidly and to
address directly androgen synthesis or actions by using
agents that alter (1) synthesis of androgens, (2) conversion of
testosterone to its more active metabolites, (3) aromatization
of androgens to estrogens, (4) androgen receptor action, and
(5) estrogen receptor action.
4.2.1. Inhibitors of Adrenal Androgen Synthesis. Of the
adrenal androgen synthesis inhibitors, ketoconazole has
been the most widely studied [50]. An azole antifungal
drug, ketoconazole at high doses is capable of lowering
both testosterone and DHEA (dihydroepiandosterone) by
inhibiting the cholesterol side chain cleavage enzyme, 17-
α hydroxylase, and 17, 20 lyase. While eﬀective in lowering
adrenal androgen production, the use of ketoconazole in
clinical practice is complicated with its dose-limiting side
eﬀects such as fatigue, neurotoxicity, hepatotoxicity, and
nausea. Its absorption is erratic and it can interfere with
the P450-dependent metabolism of many drugs. In addition,
(although not critical to patients with CAH) ketoconazole
can reduce cortisol synthesis suﬃcient to necessitate the need
for corticosteroid replacement in most patients [51]. Keto-
conazole, in more modest doses used for other indications in
children, has a relatively benign side-eﬀect profile. However,
the dose to suppress adrenal steroid synthesis would be
higher and require close monitoring for severe side eﬀects
such as hepatotoxicity. Nevertheless, the use of ketoconazole
as an adjuvant therapy in CAH warrants investigation.
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Abiraterone acetate is an orally available, potent,
selective, high aﬃnity, irreversible inhibitor of the 17α-
hydroxylase and C17, 20-lyase (CYP450c17) enzymes [52].
Abiraterone acetate is approximately six to seven times more
potent in inhibiting CYP450c17 than ketoconazole [53].
Preclinical and phase I studies in patients with prostate
cancer showed that abiraterone eﬀectively suppresses testos-
terone production in the adrenal gland, and doses of up
to 2000 mg/d were tolerated [54]. Adverse eﬀects (e.g.,
hypertension, edema, and hypokalemia) associated with
abiraterone use are related to the increased production of
nonandrogenic steroids as a result of downstream defect
on mineralocorticoid secretion created by inhibition of
17α-hydroxylase activity [55]. Although such an enzymatic
blockade could be problematic in a number of conditions,
it should not be a clinically significant problem in patients
with classical 21-hydroxylase deficiency because aldosterone
synthesis is already impaired. Abiraterone is a promising
agent for the management of CAH, but it requires studies
of safety and eﬃcacy in children with CAH.
4.2.2. Androgen Receptor Antagonists. Flutamide, an
androgen-receptor blocker, has been used to treat
children with CAH as part of a four-drug regimen,
including testolactone (an aromatase inhibitor), low-dose
hydrocortisone, and fludrocortisone. Short-term results are
encouraging and showed improved control of height velocity
and bone maturation at reduced glucocorticoid dosage [56].
More potent antiandrogens are now available that are
in use for the treatment of prostate cancer. Nilutamide,
a derivative of flutamide, has pharmacokinetic properties
allowing once-daily dosing. Bicalutamide, also derived from
flutamide, has two-times increased aﬃnity for the androgen
receptor, as compared with flutamide and nilutamide, a
longer half-life (one week), and significantly decreased
toxicity, most notably in hepatotoxicity. Both nilutamide and
bicalutamide have been used eﬀectively in the treatment
of prostate cancer [57, 58] and have potential in the
management of CAH, although the safety and eﬃcacy in the
treatment of CAH is not known.
MDV3100 is the most recently developed antiandro-
gen agent. It binds androgen receptors with an eight-
fold higher aﬃnity than does bicalutamide. While other
antiandrogens show androgen-receptor agonist properties
under some experiment conditions, MDV3100 appears to be
a true androgen-receptor antagonist because it both impairs
androgen receptor nuclear translocation and blocks DNA
binding without apparent agonist properties. The phase 1/2
trials of MDV3100 in patients with prostate cancer show
promising results [50]. Again, the role in the management
of CAH has yet to be studied.
4.2.3. 5-α Reductase Inhibitors. Inhibitors of the enzyme 5-
α reductase include finasteride and dutasteride [59]. They
block the conversion of testosterone to its active form,
dihydrotestosterone (DHT). 5-α reductase inhibitors reduce
androgen action on peripheral tissues and may have a role
in alleviating the consequences of hyperandrogenism in
patients with CAH. These drugs, however, are contraindi-
cated in females of child-bearing age due to their capacity
to cross the placenta and induce ambiguous genitalia in the
fetus.
4.3. Aromatase Inhibitors (AIs). Aromatase Inhibitors (AIs)
act by inhibiting P450 aromatase, the enzyme that catalyzes
the aromatization of C19 androgens (androstenedione,
testosterone) to C18 estrogens (estrone, estradiol). The initial
uses for AIs included estrogen-dependent breast cancer [60]
and gynecomastia [61]. The expansion of AI use to other
conditions has evolved with the development of selective
inhibitors of aromatase. The capacity of AIs to decrease
estrogen, as well as their eﬀect on the maturation of growth
plates, led to the study of the capacity of AIs to prolong
linear growth in children with short stature of a variety of
etiologies, including CAH [62, 63].
Evidence for the eﬃcacy began with investigation of the
nonselective first generation AI, testolactone with positive
eﬀects on growth, and PAH in male central precocity
(reviewed in [64]). Examination of testolactone therapy
in girls with McCune Albright syndrome also showed an
improved PAH [65]. Moreover, a study of testolactone in
CAH suggested a positive eﬀect when used in conjunction
with an androgen receptor antagonist although three-time-
daily dosing proved a hindrance with compliance [56, 66].
After 2 years, the group that is receiving the experimental
treatment regimen had elevated blood androgen levels, but
linear growth rate and bone maturation were normal. No
significant long-term adverse eﬀects were seen.
Third generation AIs appear to be better tolerated and
require only once-daily dosing. Selective third-generation
AIs have been used in several short stature conditions,
including constitutional delay of growth and puberty [67–
69], idiopathic short stature, and growth hormone deficiency
[70, 71]. These studies reported that treatment with the AIs
letrozole or anastrozole result in improved PAH. The role of
these selective AIs warrants controlled longer-term studies in
CAH. Further studies of AIs also are warranted in conditions
more comparable to CAH such as central precocious puberty
and in gonadotropin-independent precocity, such as in
McCune Albright syndrome. As in CAH, these disorders are
associated with advancement in bone age (BA) that truncates
the time of linear growth and leads to diminished adult
stature. A significant goal of AI therapy is to permit a child’s
chronologic age (CA) to “catch-up” with their BA, such that
PAH is improved [64, 72].
Study of anastrozole in male rats showed an increase in
testosterone and decrease in estrogen levels, and an elevation
in FSH is likely due to diminished E2 levels. Inhibin B
showed no significant change in the rats and spermatogenesis
appeared grossly normal [73]. In contrast, in a study of
boys with delayed puberty, letrozole resulted in increased
LH concentrations and LH pulse amplitude [67]. Dunkel
[62] reported no adverse eﬀects on testicular size or inhibin
B levels in boys. The rise in LH, in addition to elevation
in testosterone levels, has raised the theoretical concern
that letrozole may result in a PCOS-like picture in girls. In
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contrast, the use of AIs is currently under investigation to
improve fertility in women with PCOS [74]. The potential
teratogenic eﬀects of AIs are, however, unknown [75, 76].
The consensus statement by Lawson Wilkins Pediatric
Endocrine Society [77] outlined the following concerns on
the use of AIs in short stature: (1) all of the data derived
from interventions are limited to male patients; (2) only
two randomized, double-blinded, placebo-controlled trials
were performed, and relatively small number of subjects
were treated with AIs; (3) very few patients have been
followed to near-adult height, and adult heights from the
controlled trials are not available; (4) short-term safety
data are reassuring; however, long-term data are lacking.
Therefore, AIs are not recommended to be used in females.
Long-term studies addressing concerns on their eﬃcacy and
safety in both prepubertal and pubertal boys and girls are
needed before AI use becomes more widespread.
4.4. Estrogen Receptor Blockers. Estrogen receptor block-
ers, like aromatase inhibitors, may have a place in
the management of CAH with the goal of delaying
androgen-induced rapid skeletal maturation. Many selec-
tive estrogen receptor modulators (SERMs) are avail-
able. Triphenylethylenes (Tamoxifen, Droloxifene, Idoxifene,
Toremifene, and Ospemifene), Benzothiophenes (Ralox-
iphene, Arzoxifene), and Benzopyrans (Ormeloxifene, lev-
ormeloxifene) are eﬀective in blocking estrogen action in
breast cancer but have agonistic actions in other tissues
including skeletal system [78, 79]. Although their eﬀect on
skeletal maturation has not been studied, it is likely that
those agents will have no or little eﬀect in delaying bone
age maturation. Fulvestrant, the only steroidal antiestrogen,
is unique among this category of drugs in that it is a
powerful antiestrogen that binds with high aﬃnity to the
estrogen receptor but initiates no apparent estrogen agonist
activity [80, 81]. As might be expected, therefore, fulvestrant
has been reported to block the estradiol-accelerated skeletal
maturation in prepubertal mice [82]. Although its eﬀect on
compromising the androgen-accelerated skeletal maturation
in the same model was mild [83], fulvestrant seems to be the
best candidate among estrogen receptor blockers to prevent
rapid androgen-induced acceleration in skeletal maturation
in children with CAH.
5. Bilateral Adrenalectomy
The rationale for bilateral adrenalectomy in patients with
CAH is similar to other conditions with hormonal overpro-
duction such as hyperthyroidism, acromegaly, hyperprolacti-
noma, primary hyperaldosteronism, or Cushing’s disease in
which the hyperfunctioning endocrine organ is removed,
and a replacement therapy is started for the resulting
hormonal deficiency. In CAH, bilateral adrenalectomy aims
to eliminate androgen excess. Other supportive arguments
for adrenalectomy are the observations that the management
of adrenal insuﬃciency is less problematic compared to
CAH because lower GC doses are necessary, and salt-
losing crisis are less likely. Potential problems with bilateral
adrenalectomy include surgical risk and higher risk of
adrenal crisis because the majority of patients with CAH
make some endogenous cortisol and aldosterone, potential
reduction in ability to respond to stress due to epinephrine
deficiency resulting from removal of the adrenal medulla and
the potential for Nelson syndrome and adrenal rest tumors if
ACTH suppression is not maintained.
Experience with bilateral adrenalectomy in CAH is
limited to relatively small case series and individual case
reports. VanWyk and Ritzen [84] reported follow-up studies
in 18 patients who underwent bilateral adrenalectomy for
CAH. A total follow-up of 90 patient-years was available
and showed that adrenalectomy is a safe procedure in CAH
patients with a good quality of life and health benefits.
Signs of androgen excess decreased with much lower doses
of glucocorticoid, and obesity was a less common problem.
No serious peri- or postoperative morbidity was reported.
While most patients had high ACTH levels and hyperpig-
mentation initially after adrenalectomy, particularly when
the HC dose was reduced to <10mg/m2, adequate dose
adjustment solved this problem. Adrenal rest tumor was
found in one case, but eight patients had high postoperative
elevations of steroid precursors suggesting the presence of
adrenal rest tumors. Since this initial report more cases have
been documented with similar results including its use to
successfully treat infertility in two females with CAH [85–
87]. Laparoscopic adrenalectomy has reduced perioperative
morbidity; however, adrenal rest tumors and corticotrophin
hypersecretion in association with a pituitary microadenoma
have been reported [88]. In contrast to legitimate concerns,
no problems with epinephrine deficiency are reported and
may be explained by the findings that patients with CAH
on GC replacement already have greatly reduced secretion of
epinephrine [89].
In addition to its use in patients who are intractable
to conventional treatment, bilateral adrenalectomy as a
“prophylactic” measure in young children with double null
mutations of their CYP-21 gene is under evaluation. The
rationale is to prevent potential virilization due to inadequate
suppression of androgens and/or iatrogenic glucocorticoid
excess before they occur in severe cases of CAH. Two patients
underwent prophylactic adrenalectomy younger than 5 years
of age. The youngest patient who was adrenalectomized at
16 months had two episodes of hypoglycemia on low dosage
of HC (8mg/m2), which did not recur after HC dosage was
increased (11–13mg/m2) throughout her 6-year follow-up
after adrenalectomy. The first patient who had prophylactic
adrenalectomy at 3 years of age is now 16 years old. She
has reached her midparental height and has normal menses
and no signs of hyperandrogenism. She, however, continues
to have elevated ACTH levels while on replacement dose of
glucocorticoid and mineralocorticoid [90].
Bilateral adrenalectomy appears to be a safe and eﬃ-
cacious method of managing patients with severe forms
of CAH. Long-term studies comparing this approach with
other treatment modalities, however, are lacking. Undoubt-
edly, adrenalectomized patients should be monitored closely
with meticulous management of glucocorticoid and min-
eralocorticoid replacement and prompt institution of stress
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dosages at the onset of illness. Prophylactic adrenalectomy of
young patients may be a viable option in the future if its long-
term safety is established but currently should be limited to
academic centers with established research protocols.
6. Gene Therapy
As other disorders caused by a single gene defect, gene
therapy is theoretically possible for all forms of CAH. The
development of gene therapy requires an animal model to
test the strategy, and a specific, eﬀective, and safe vector
to deliver the gene. Both are available for 21-hydroxylase
deficiency. Themouse strain H-2aw18, a recombinantmouse
line that has a deletion spanning the C4 gene and one of
the two 21-hydroxylase gene, shows typical characteristics
of 21-hydroxylase deficiency. Introducing a recombinant
DNA fragment containing the murine genomic gene for 21-
hydroxylase rescued the lethal mutation and showed that
this mouse line is a valid model to study gene therapy
[91]. Adenoviruses have selective adrenotropism in animals
making them a good vector for gene therapy [92, 93]. Indeed,
intra-adrenal injection of adenoviral vector encoding the 21
hydroxylase gene has restored the impaired adrenocortical
function in these 21-hydroxylase deficient mice [94], and
bovine adrenocortical cells have shown functional and mor-
phological changes in the adrenal cortex after transfection
with recombinant adenoviruses [95]. The experience with
adenoviruses to target 21-hydroxylase to the adrenal cells is
encouraging, but overall safety and specificity in targeting
the adrenal gland remain unclear. There may be a need
to develop new vectors (viral or non-viral) to improve the
specificity and eﬃciency of gene transfer in adrenal gland and
to ensure long-term DNA integration. In recent years, other
recombinant viruses such as retrovirus, lentivirus, adeno-
associated virus, and herpes simplex virus have been widely
utilized as vectors for gene transfer. Nonviral gene delivery
methods that use synthetic or natural compounds or physical
forces to deliver DNA to a cell have become available. While
gene therapy is likely to become an option for the treatment
of CAH with these advances, the research specific to the gene
therapy in CAH appears to be sparse.
7. Stem Cells and CAH
Adult stem cells are derived from specific tissues and
have been studied in many venues, particularly that of
the hematopoietic system. Limitations of adult stem cells
include (1) lack of pluripotency, (2) diﬃculty to maintain
in vitro, and (3) HLA-limitations for transplantation, thus
requiring concomitant immunosuppression [96]. Studies
using marrow-derived mesenchymal stem cells (MSCs)
have provided an additional avenue in that they can be
harvested from adults yet are still considered pluripotent
[97]. More recent studies have suggested general methods
for preparation of induced pluripotent stem cells (IPSCs)
from other somatic cell lineages [98]. Note that any cells
that are harvested from patients with CAH, either MSCs or
IPSCs, could be used as allografts (avoiding issues with HLA
compatibility) but would still harbor a genetic deficiency in
steroidogenesis and thus would only be useful as cellular
vectors for gene therapy. Despite this, use of adult stem cells
benefits from a longer track record of investigation and also
circumvents ongoing political obstacles regarding the use of
fetal tissue.
In contrast, embryonic stem cells (ESCs) provide an
approach that could bypass many of the restrictions of adult
stem cells [96]. ESCs obtained during the blastocyst stage
are logistically easier to maintain and cultivate in vitro and
can remain for a longer period in the pluriopotent stage.
In principal, ESCs could be triggered to diﬀerentiate into
regulated, steroidogenic tissue using protocols derived from
adult stem cell studies [99]. However, as with adult tissue
transplants, HLA-matching is required with potential for
graft rejection and necessitates immunosuppressive agents.
The next generation of ESCs, however, is those that are
HLA matched and, therefore, bypass immunosuppressive
regimens after transplantation.
Yazawa et al. [97] showed that human MSCs trans-
fected with SF-1, necessary for both gonadal and adrenal
steroidogenesis, diﬀerentiated into GC-producing (versus
testosterone-producing) cells when transplanted intomurine
testis. Gondo et al. [100] also used SF-1 to produce steroido-
genic cells from MSCs; moreover, the cells were responsive
to stimulation by ACTH. The authors then reported that a
diﬀerential hormonal profile was synthesized by transformed
stem cells derived from bone marrow than from those
derived from adipose stem cells, suggesting that site of stem
cell origin is important in determining which steroidogenic
pathways can be induced [101].
An additional approach is that of Hammer and col-
leagues, who have characterized a subpopulation of adrenal
cells that are typically undiﬀerentiated or “dormant” [102,
103]. Stimulation of these cells to diﬀerentiate into mature
adrenal cells under various physiologic or pathophysiologic
conditions may be possible, and studies aimed at harvesting
this quiescent population for both diﬀerentiation and/or
regeneration of adrenal tissue are targets for both CAH and
for adrenal insuﬃciency of other etiologies [101–103].
The potential use of stem cells to provide functional
adrenal cortical tissue would, if realized, represent a cure for
CAH. A key to the success of such an approach would be
to provide adrenal tissue that responded in a physiological
fashion to both positive and negative regulators.
8. Conclusion
Although introduction of glucocorticoid and mineralocorti-
coid treatment markedly decreased mortality and morbid-
ity of patients with CAH, management of CAH remains
challenging. Clinicians are often frustrated by the diﬃculties
in maintaining satisfactory adrenal suppression without
producing an unacceptable degree of hypercortisolism.
Shortened adult stature and progressive obesity are common.
Novel treatments with great potential to improve outcomes
are available, but their use is hampered by the lack of
studies in the CAH population. Most clinical trials to date
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suﬀer from relatively small sample sizes and/or retrospective
approach. Prospective, randomized, placebo-controlledmul-
ticenter trials are required to interpret the appropriate use of
these promising agents in children with CAH. Unfortunately,
funding is sparse, and the pharmaceutical industry has little
interest in investing such a small population of patients. It is
critical, therefore, that pediatric endocrinologists, patients,
and their families, in addition to advocacy groups, continue





CAH: Congenital Adrenal Hyperplasia
CRH: Corticotropin Releasing Hormone
GC: Glucocorticoid
GnRH: Gonadotropin Releasing Hormone
HC: Hydrocortisone.
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